The opening of hemophilia B gene therapy trials to patients with little to no access to conventional treatments would be a pioneering advancement.
Senators Baldwin (D-WI) and Jones (D-AL) have introduced the No Junk Plans Act.
The updated trial data shows three individuals with hemophilia B responding well to a one-time treatment with their investigational gene therapy AMT-061.
Researchers in Iran hope to achieve better outcomes for this vulnerable patient subgroup.
The investigators are working to build on factor VIIa’s established utility to stem bleeding, to one that can also prevent bleeding in both hemophilia A and B patients.
NHF has been leading efforts to fight co-pay accumulator programs since their inception.
Jumo Health and NHF seek to increase health literacy with the release four evidence-based comic books for those managing hemophilia.
Loss of patient protections would raise barriers to health insurance.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car